Physicians’ Knowledge About FDA Approval Standards and Perceptions of the “Breakthrough Therapy” Designation-Reference-Cited by-同舟云学术

Physicians’ Knowledge About FDA Approval Standards and Perceptions of the “Breakthrough Therapy” Designation

Published:2016-04-12 Issue:14 Volume:315 Page:1516
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Kesselheim Aaron S.¹,Woloshin Steven²,Eddings Wesley¹,Franklin Jessica M.¹,Ross Kathryn M.³,Schwartz Lisa M.²

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts

2. Center for Medicine and the Media, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire3Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

3. American Board of Internal Medicine, Philadelphia, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Balancing ethical norms and duties for the introduction of new medicines through conditional marketing authorization: a research agenda;Frontiers in Medicine;2024-06-24

2. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price;Journal of the National Comprehensive Cancer Network;2024-05

3. Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D;Journal of Health Economics;2024-03

4. High cost oncology drugs without proof of added benefit are burdening health systems;BMJ;2024-02-29

5. US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion;BMJ;2024-02-21